Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
TORONTO, Nov. 13, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) under the […]
FSD Pharma, Inc (CSE: HUGE) (OTC: FSDDF) CEO Interview with Dr. Raza Bokhari. FSD Pharma is building the worlds largest licensed indoor cannabis growing facility […]
InnerScope and Erchonia have entered into Joint Development & Exclusive Distribution Agreements and intend to obtain a 510k FDA-Clearance via clinical trial to study the effect on using Erchonia’s Low-Level Laser Therapy Technology for […]
Innerscope Hearing Technologies (OTC: INND) CEO Interview with Matthew Moore, discussing consolidation opportunity in $4billion US hearing aid market, Walmart online distribution […]
Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative. Investor Presentation Deck
Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018
Cathie Wood, of ARK Genomic Revolution ETF(NYSE: ARKG) explains the multi-trillion dollar opportunity in the Genomics Revolution: CAR-T, CRISPR, and DNA Sequencing
Celyad (NASDAQ: CYAD) CEO Christian Homsy shares his vision for universal CAR-T
How to Trade Biotech and Pharmaceutical Stocks Profiting from the FDA approval cycle
Exelixis (NASDAQ: EXEL) CEO Michael Morrissey gives an update on cabozantinib
PALATINE, Ill., Jan 08, 2018 -Acura Pharmaceuticals, Inc. (OTC QB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from clinical study AP-LTX-301 (Study 301) for its LIMITx(TM) excess oral […]
Acura Pharmaceuticals, Inc (NASDAQ:ACUR)
Interview with Bob Jones, CEO […]
Fluoro Pharma Medical (OTCBB:FPMI)
Interview with Thijs Spoor, CEO and Chairman […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
